Renal cell carcinoma (RCC) encompasses a hetero geneous group of cancers derived from renal tubular epithelial cells 1 and is among the 10 most common cancers worldwide. Key advances in histopathological and molecular characterization of RCC over the past two decades have led to major revisions in its classifi cation [2] [3] [4] [5] . Major subtypes 6 with ≥5% incidence are clear cell RCC (ccRCC) 7 , papillary RCC (pRCC) 8 and chromo phobe RCC (chRCC) 9 (FIG. 1) . The remaining subtypes are very rare (each with ≤1% total incidence) 5 , and in cases in which a tumour does not fit any subtype in the diagnostic criteria, it is designated as unclassi fied RCC (uRCC; ~4% total incidence) 10 . ccRCC is the most common subtype and accounts for the majority of deaths from kidney cancer and is the focus of this Primer 11 . Indeed, owing to the predomin ance of clear cell histology in metastatic disease (83-88%) 12,13 , tumours with nonclearcell histology have been grouped as 'nccRCC' (TABLE 1) for feasibility in con ducting clinical trials [14] [15] [16] . Furthermore, recent cancer genomic studies have revealed an overt complexity of intratumour [17] [18][19] and intertumour 7, 20 heterogeneity in ccRCC, which could contribute to the heterogeneous clinical outcomes observed [21][22][23] . Localized RCC can be treated with partial or radical nephrectomy (removal of the kidney) 24 , ablation (destruc tion of the malignant tissue with heat or cold) 25 or active surveillance (monitoring of tumour growth with periodic radiographic studies) 26 . Despite nephrectomy with cura tive intent, ~30% of patients with ccRCC with localized disease eventually develop metastases [27] [28] [29] [30] , which require systemic therapies and are associated with high mortality. Targeted therapies against vascular endothelial growth factor (VEGF) and mechanistic target of rapamycin (mTOR) pathways have been developed, but treatment response is varied and most patients eventually pro gress 31 . However, increased genomic and molecular understanding of metastatic ccRCC has contributed to an unprecedented number of drug approvals in the United States and European Union (currently, 12 approved drugs with six different effective mechanisms of action are approved). In this Primer, we discuss these new approv als and the major progress that has made in the biology of ccRCC that led to their development. Furthermore, we present insights into genomicbased risk and treat ment stratification and discuss treatment sequencing and combinations that are paving the way for the future design of personalized clinical management plans. Abstract | Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and accounts for >90% of cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, of which clear cell RCC (ccRCC) is most common and accounts for most cancer-related deaths. Although somatic VHL mutations have been described for some time, more-recent cancer genomic studies have identified mutations in epigenetic regulatory genes and demonstrated marked intra-tumour heterogeneity, which could have prognostic, predictive and therapeutic relevance. Localized RCC can be successfully managed with surgery, whereas metastatic RCC is refractory to conventional chemotherapy. However, over the past decade, marked advances in the treatment of metastatic RCC have been made, with targeted agents including sorafenib, sunitinib, bevacizumab, pazopanib and axitinib, which inhibit vascular endothelial growth factor (VEGF) and its receptor (VEGFR), and everolimus and temsirolimus, which inhibit mechanistic target of rapamycin complex 1 (mTORC1), being approved. Since 2015, agents with additional targets aside from VEGFR have been approved, such as cabozantinib and lenvatinib; immunotherapies, such as nivolumab, have also been added to the armamentarium for metastatic RCC. Here, we provide an overview of the biology of RCC, with a focus on ccRCC, as well as updates to complement the current clinical guidelines and an outline of potential future directions for RCC research and therapy. NATURE REVIEWS | DISEASE PRIMERS VOLUME 3 | ARTICLE NUMBER 17009 | 1 PRIMER © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .
, papillary RCC (pRCC) 8 and chromo phobe RCC (chRCC) 9 (FIG. 1) . The remaining subtypes are very rare (each with ≤1% total incidence) 5 , and in cases in which a tumour does not fit any subtype in the diagnostic criteria, it is designated as unclassi fied RCC (uRCC; ~4% total incidence) 10 . ccRCC is the most common subtype and accounts for the majority of deaths from kidney cancer and is the focus of this Primer 11 . Indeed, owing to the predomin ance of clear cell histology in metastatic disease (83-88%) 12, 13 , tumours with nonclearcell histology have been grouped as 'nccRCC' (TABLE 1) for feasibility in con ducting clinical trials [14] [15] [16] . Furthermore, recent cancer genomic studies have revealed an overt complexity of intratumour [17] [18] [19] and intertumour 7, 20 heterogeneity in ccRCC, which could contribute to the heterogeneous clinical outcomes observed [21] [22] [23] . Localized RCC can be treated with partial or radical nephrectomy (removal of the kidney) 24 , ablation (destruc tion of the malignant tissue with heat or cold) 25 or active surveillance (monitoring of tumour growth with periodic radiographic studies) 26 . Despite nephrectomy with cura tive intent, ~30% of patients with ccRCC with localized disease eventually develop metastases [27] [28] [29] [30] , which require systemic therapies and are associated with high mortality. Targeted therapies against vascular endothelial growth factor (VEGF) and mechanistic target of rapamycin (mTOR) pathways have been developed, but treatment response is varied and most patients eventually pro gress 31 . However, increased genomic and molecular understanding of metastatic ccRCC has contributed to an unprecedented number of drug approvals in the United States and European Union (currently, 12 approved drugs with six different effective mechanisms of action are approved). In this Primer, we discuss these new approv als and the major progress that has made in the biology of ccRCC that led to their development. Furthermore, we present insights into genomicbased risk and treat ment stratification and discuss treatment sequencing and combinations that are paving the way for the future design of personalized clinical management plans.
Epidemiology

Incidence and mortality
Kidney cancer accounts for ~2% of all cancer diagnoses and cancer deaths worldwide, with incidence rates gen erally higher in developed countries 32 (FIG. 2) . Annually, ~295,000 new kidney cancer cases are diagnosed and ~134,000 deaths are recorded worldwide 33, 34 . Kidney cancer accounts for ~63,000 new cases and ~14,000 deaths yearly in the United States 35 , and for ~84,000 new cases and ~35,000 deaths in Europe 36 . Men are more affected than women (a 2:1 ratio of new diagnoses).
The median age of patients with RCC in the Surveillance, Epidemiology, and End Results (SEER) database in the United States was 64 years with a nearnormal distribution 37 . Accordingly, when RCC is diagnosed at younger ages (≤46 years, which represents the lowest decile of the age distribution) 37, 38 , the possibil ity of an underlying hereditary kidney cancer syndrome -which accounts for 3-5% of all RCCs 5 -should be considered 39, 40 (TABLE 2) .
The incidence of RCC is highest in the Czech Republic, with agestandardized annual rates of 22.1 and 9.9 new cases per 100,000 men and women, respectively, over the period [2003] [2004] [2005] [2006] [2007] (REF. 41 ). The incidence is also very high in the Baltic and eastern European countries, although the reasons for this excess are not known. Overall, incidence rates have been increasing over time in most populations, but mortality rates have levelled off or have been decreasing since the 1990s. This divergent pattern of increasing incidence and decreasing mortal ity is particularly evident in developed countries. For example, analyses within the SEER database indicate that the increase in RCC incidence is confined to small and localized tumours, probably owing, at least in part, to the increasingly frequent incidental detection -from increased use of abdominal imaging -of small renal masses (tumours ≤4 cm in size) that are unlikely to have metastasized 42 . The global increases in the prevalence of obesity, an established RCC risk factor, might also play a part in increasing incidence, as well as in influencing clinical outcome 41, 43 .
Risk factors
RCC incidence increases markedly with age and is higher for men than for women. In the United States, inci dence varies by ethnic group, with rates highest among Native Americans, Indigenous Alaskans and African Americans, and are lowest among Asian Americans and people of Pacific Island descent 35 . The major estab lished risk factors for RCC include excess body weight, hypertension and cigarette smoking 44 , which were factors in approximately half of all diagnosed cases in one US study 45 . Other medical conditions that have been associ ated with RCC in epidemiological studies include chronic kidney disease, haemodialysis, kidney trans plantation, acquired kidney cystic disease, a previous RCC diagnosis and, possibly, diabetes mellitus 44 . Many lifestyle, dietary, occupational and environ mental factors have also been associated with RCC with varying levels of evidence 46 . For example, contradictory reports exist on the association between red meat con sumption and RCC risk 47, 48 . Moderate alcohol consump tion (≥11 g per day) seems to reduce the risk for RCC 48, 49 .
In a case-control study on physical activity and the risk of RCC, inverse trends in risk were found, and the authors concluded that 9% of RCC cases could be avoided by increasing physical activity 50 . However, the inverse associ ation might have involved other confounding factors, such as body mass index (BMI) and social class correlates. Other studies have found no such inverse association 51 .
Genetic factors also contribute to RCC risk, as evi denced by individuals with a family history of renal cancer having an approximate twofold increased risk 52 .
Investigations into familial RCC have uncovered muta tions in at least 11 genes (BAP1, FLCN, FH, MET, PTEN, SDHB, SDHC, SDHD, TSC1, TSC2
and VHL), some of which have also been implicated in spor adic RCC develop ment 39 . A notable example is VHL (which encodes pVHL), the mutated gene underlying von Hippel-Lindau disease, which is characterized by a high risk of developing ccRCC 53 ; inactivation of pVHL, which leads to the unchecked expression of oncogenic hypoxiainducible factor 1 (HIF1) and HIF2, is also a hallmark of sporadic ccRCC tumours (see Mechanisms/ pathophysiology) 39, 54 . Genomewide association studies (GWAS) of RCC have identi fied six susceptibility loci to date, on chromosome regions 2p21, 2q22.3, 8q24.21, 11q13.3, 12p11.23 and 12q24.31 . The 2p21 locus maps to EPAS1, which encodes the HIF2α sub unit 55 , whereas the bio logical effects underlying the 11q13.3 locus seem to be attributable to changes in the regulation of CCND1 (encoding cyclin D1, which is involved in cell cycle regulation) 59 . The locus 12p11.23 probably maps to changes in BHLHE41 (encoding basic helix-loop-helix family member e41, which is thought to have a role in the regulation of the circa dian rhythm) 60 . The disease genes underlying the other GWAS susceptibility loci have yet to be identified.
Mechanisms/pathophysiology
Genes and pathways
In ccRCC, the VHL tumour suppressor gene is the most frequently mutated gene 7, 54 , and its complete loss through genetic (point mutations, insertions and dele tions (indels) and 3p25 loss) and/or epigenetic (pro moter methylation) mechanisms constitute the earliest, truncal oncogenic driving event 61, 62 . VHL is the sub strate recognition component of an E3 ligase complex that ubiquitylates HIF1α and HIF2α for proteasome mediated degradation 53, 63, 64 . Thus, loss of VHL leads to the aberrant accumulation of HIF proteins despite an adequately oxygenated tissue microenvironment, which in turn results in uncontrolled activation of HIF target genes that regulate angiogenesis, glycolysis and apoptosis (FIG. 3) . Accordingly, human ccRCC tumours are rich in lipids and glycogens, and are highly vascular 65, 66 -which underlies why agents that primarily inhibit VEGF and its receptor VEGFR are effective treatments for meta static ccRCC 14, 15, 67 . However, VHL loss alone is insuffi cient to induce ccRCC, as evidenced by the long latency (>30 years) in individuals who harbour VHL germline mutations to develop ccRCC 53 and by the observation that Vhl loss in mice is unable to induce ccRCC 68 . These results suggest that additional genetic and/or epigenetic events are probably needed for ccRCC to develop 69 . To identify these events, largescale cancer genomic projects have been undertaken and have revealed several novel prevalent mutations in ccRCC, includ ing PBRM1 (29-41% of tumour samples), SETD2 (8-12%), BAP1 (6-10%), KDM5C (4-7%) and MTOR (5-6%) 7, [70] [71] [72] [73] . Interestingly, PBRM1, SETD2 and BAP1 encode chromatin regulating and histoneregulating proteins, are located at 3p21 and function as tumour suppressors 7, [70] [71] [72] . As VHL resides at 3p25, a single copy loss of the short arm of chromosome 3 (3p) would result in haploinsufficiency of these four tumour suppressor genes, corroborating the fact that 3p loss (that is, loss of heterozygosity) is nearly a universal event in ccRCC 61 and constitutes an early genetic event 69 . By contrast, MTOR mutations in ccRCC are generally missense and functionally activating 73, 74 , which could explain the reason why mTOR pathway inhibitors, including everolimus and temsirolimus, are effective 75, 76 . How individual mutations and their interactions con tribute to the pathogenesis and their values as prognostic or predictive biomarkers in ccRCC are largely unknown. Nevertheless, a few studies have demonstrated interest ing clinical correlations that warrant future validation. As inactivation of VHL is the founding event of ccRCC, its mutation status has no effect on clinical outcome, whereas mutations involved in disease progression, such as PBRM1, SETD2 and BAP1 as well as KDM5C (which is also involved in chromatin modification), were shown to associate with aggressive clinical features [77] [78] [79] . Small renal masses harbouring PBRM1 mutations were associ ated with stage III pathological features (that is, extra renal growth but not extending beyond Gerota's fas cia, see below) 71 , whereas BAP1 mutations were associated with larger tumour sizes, higher Fuhrman nuclear grade (that is, a large nucleus with a prominent nucleolus) and worse cancerspecific survival 77, 78, 80 . Interestingly, muta tions in BAP1 and PBRM1 (REF. 70) Tumour heterogeneity and cancer evolution As Nowell first described 40 years ago 81 , genetic diver sity within tumours is thought to provide the substrate upon which selection can act, to enable tumours to adapt to new microenvironmental pressures and metabolic demands during the natural history of the cancer (FIG. 4a) . Such genetic diversity has been studied extensively in ccRCC. For example, in a study of four patients with ccRCC who had multiple tumours and were subjected to multiregion genetic analysis, VHL mutation and 3p loss of heterozygosity were found to be ubiquitous events across all regions sampled 17 . By contrast, common driver events, such as SETD2, PBRM1, MTOR, PIK3CA, PTEN and KDM5C mutations, were present heterogeneously within the primary tumour and metastatic sites -in some regions but not others. Such genetic characteristics enable the construction of tumour phylogenies, whereby the 'trunk' of the evolutionary tree depicts mutations found in the most recent common ancestor (MRCA) that are also present in every tumour cell. 'Branched' mutations are found in some subclones but not others; these mutations may be regionally distributed across the tumour, occupying distinct regional niches within the primary tumour or different niches between the primary and metastatic sites of disease.
Furthermore, parallel evolution has been observed, whereby recurrent branch alterations in subclones affect the same gene, the signal transduction pathway or the protein complex (FIG. 4b) . In some cases -such as BAP1, PBRM1 and SETD2 mutations -such recur rent but distinct alterations can be readily explained as the 'secondhit' event in the evolution of the tumour. In other cases, parallel evolution suggests considerable selection pressures for disruption of the same signalling pathway or protein complex. In addition, convergence of genetic characteristics has been noted in several studies of ccRCC 19, 23, 82 , whereby mutations in genes occur at dif ferent time points but result in similar overall genomic and phenotypic profiles; a 'braided river' model has been conceived to illustrate this phenomenon 69 (FIG. 4c) .
Regardless of the modality, a followup study of ccRCC samples from eight patients demonstrated evidence for branched evolution, in which 73-75% of driver alterations were found to be subclonal 18 . Multiregion tumour analyses suggest the intriguing possibility that evolutionary trajectories are remarkably constrained in ccRCC, which -as our knowledge of microenvironmental, therapeutic and host selection pressures grows -could render the evolutionary routes predictable and, therefore, therapeutically tractable. For example, it has been shown that patients who responded well to mTOR inhibition harboured recurrent regionally separated aberrations in components of the mTOR path way 75 . Furthermore, some subclonal alterations might be involved in the initiation and maintenance of cellto cell variation that are necessary for clonal selection. For example, SETD2 loss of function has been shown to impair nucleosome compaction, mini chromosome maintenance complex component 7 (MCM7) function and DNA polymeraseδ loading to chromatin, result ing in impaired DNA replication fork progression. In addition, failure to load lens epitheliumderived growth factor p75 splice variant (LEDGF; also known as PSIP1) and DNA repair protein RAD51 homologue 1 (RAD51) -which are involved in DNA break repairhas also been observed upon SETD2 loss, resulting in homologous recombination repair deficiency 83 . These events are, accordingly, plausible genomic biomarkers in ccRCC that are dispersed within distinct regional niches within each tumour 19, 84 . . Of these, perhaps the immune infiltration character istics of ccRCC are of increasing interest, given the rise of immune checkpointblocking therapies in this disease (see below, Management). Notably, among 19 cancer types examined by The Cancer Genome Atlas research programme, ccRCC has the highest T cell infiltration score 87 . Furthermore, higher nuclear grade and stage in ccRCC were correlated with an increase in T helper 2 cell and regulatory T cell infiltration 87, 88 .
Disease models
Although RCC cell lines have been used for mech anistic studies 89 , ccRCC tumours in patients are highly vascular -a feature that cannot be recapitulated with in vitro cell studies. Furthermore, such cell lines can acquire additional genetic and/or epigenetic changes during passages such that in vitro drug screens do not yield speci fic, translatable insights 90 . Nevertheless, when these cell lines were injected subcutaneously into lab oratory animals, xenografted tumours largely responded to antiVEGF therapy 91 and can be used to investigate resistance mechanisms 92, 93 . More recently, patientderived xenograft models have been established and have been shown to recapitu late the patient's documented clinical response to tar geted thera pies, which could be used in preclinical drug trials 94 . At the same time, efforts to develop mouse models that truly reflect human ccRCC genomics and morpho logy have been hampered by the fact that homozygous inactivation of Vhl in mice does not result in ccRCC 68 . However, the identification of additional recurrent, preva lent mutations in human ccRCC has rekindled efforts to generate such models. For example, homo zygous deletion of Vhl and Pbrm1 in a mouse model resulted in multi focal, lipidrich, glycogen rich, transplantable ccRCC (J.J.H., unpublished observation). 
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Interestingly, homozygous deletion of Vhl and Bap1 in a mouse model resulted in early lethality (<1 month), and some mice (within a cohort of seven) carry ing homo zygous deletion of Vhl and hetero zygous deletion of Bap1 developed tumour micronodules (0.25-1.8 mm in size) with unknown tumour inci dence and molecular characteristics 95 . Overall, animal models of RCC are currently limited but are eagerly being pursued.
Diagnosis, screening and prevention Diagnosis Historically, patients were diagnosed with RCC after presenting with flank pain, gross haematuria and a palpable abdominal mass. Nowadays, the majority of diagnoses result from incidental findings. This shift is a consequence of the widespread use of non invasive radiological techniques, such as ultrasonography or abdominal CT imaging, performed for another reason. That being said, paraneoplastic syndromes -symptoms caused by hormones or cytokines excreted by tumour cells or by an immune response against the tumourare not uncommon in RCC 96 and symptoms include hypercalcaemia, fever and erythrocytosis. Most of these symptoms are usually reversed after tumour resection 11 . Diagnosis is usually strongly suspected by imaging studies; although RCCs can show variable radio graphic appearances 97 . Typical radio logical features for ccRCC include exophytic (outward) growth, hetero geneity due to intratumoral necrosis or haemor rhage and high uptake of contrastenhancement agents 98 .
Staging. The stage of RCC reflects the tumour size, the extent of invasion outside of the kidney, the involvement of lymph nodes and whether the tumour has metasta sized (FIG. 5) . CT imaging with contrast enhancement of the chest, abdominal cavity and pelvis is required for optimal staging. Such imaging enables the assessment of the primary tumour (such as the size and whether the tumour is organconfined or extends to perinephric fat or the renal hilum), regional spread (lymph node involvement) and distant metastases (including lung, bone and distant lymph nodes). MRI can also provide additional information, especially to determine whether the tumour extends into the vasculature (a vena cava tumour thrombus). Bone scan,
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Ffluorodeoxyglucose PET and imaging of the brain are not systemati cally recom mended for initial staging 14, 15 . Prognostic assessment will require further laboratory testing that includes, but is not limited to, haemoglobin levels, leuko cyte and platelet counts, serumcorrected calcium levels and lactate dehydrogenase levels 99, 100 . Treatment is largely guided by stage 15, 24 . For example, those with stage I RCC who are fit for surgery are recommended partial nephrectomy. However, radical nephrectomy is also an option; for elderly patients or those who cannot undergo surgery owing to comorbidities, active surveillance or ablative therapies are recommended. In patients with stage III RCC, radical nephrectomy is recommended with lymph node dissection in those with clinically enlarged lymph nodes, but systemic therapies might be the only available option for those with extensive disease and poor performance status. (TABLE 2) and, according to the American Society of Clinical Oncology, should trigger consideration for genetic counselling and might serve as a useful cutoff age when establishing genetic testing guidelines 37 . Indeed, aware ness of the nonrenal malignancies and nonneoplastic features associated with RCC is of interest to the physi cian to identify hereditary syndromes 40 . Furthermore, specific therapeutic options that are driven by the underlying biology are now being developed for these different RCC types related to cancer susceptibility syndromes 101 . Upon confirmation, patients and their famil ies harbour ing mutations are subject to specialized monitoring and treatment plans to minimize morbidity and prevent mortality.
Histopathological confirmation
Histopathological confirmation of malignancy is obtained either with renal core biopsy or on the partial or radical nephrectomy specimen. Initial biopsy is recom mended before ablative therapy is undertaken (in those for whom surgery is not an option) or before initiating systemic therapy (in those who have meta static disease) 102 . In 2016, the WHO classification of RCC was updated 5 . Similarly, papillary structures, which are a characteristic of pRCC, can be present in other RCC types 103 . In challenging cases, careful evaluation of cyto logical features, growth pattern, immunophenotype and genetic alterations usually enables the proper diagnosis. However, a subset of RCCs (~4%) cannot be assigned to any specific category because they either present with combined morphologies or show unusual features and are, therefore, designated uRCC 3, 104, 105 . Nevertheless, a recent molecular characterization of 62 aggressive uRCCs revealed distinct subsets, including NF2 loss (26%), mTOR complex 1 (mTORC1) pathway activation (21%) and mutations in chromatin and DNA damage regulators (21%) 10 . At macroscopic examination, the cut surface of the ccRCC tumours is golden yellow in colour with frequent haemorrhagic, necrotic and cystic areas. Microscopically, ccRCC usually consists of tumour cells with clear cyto plasm arranged in nests or tubules surrounded by a rich vascular network. The clear appearance of the cyto plasm is due to the accumulation of glycogen and lipids. A variable proportion of tumour cells with granular eosinophilic cytoplasm can be observed and, in some cases, these cells constitute the entire tumour mass 3, 104, 105 . The most widely used grading system for ccRCC is the Fuhrman grading system, which defines four nuclear grades (1-4) in order of increasing nuclear size, irregu larity and nucleolar prominence 106 . The Fuhrman nuclear grade has been shown to have prognostic value in ccRCC 30, 107, 108 . It should be noted that all RCC types can contain foci of highgrade malignant spindle cells (that is, sarco matoid differentiation). Thus, sarcomatoid RCC is no longer considered as an entity, but rather as a pro gression of any RCC type 109 . Of note, recent genomic insights from sequencingmatched sarcomatoid and carcinomatous RCC demonstrated enrichment in TP53 and CDKN2A mutations, which implicate these genetic defects as underlying causes of sarcomatoid differentiation in RCC [110] [111] [112] .
Screening
Owing to the relatively low incidence of RCC, univer sal screening (such as that for asymptomatic micro haematuria) has not demonstrated a positive effect on outcomes in RCC 113 . Furthermore, other bio markers have not yet been established for screening 114, 115 . Imaging remains the primary tool for the detection and screening of RCC. An ultrasonography screening study in 45,905 participants reported a 10fold higher RCC incidence than expected for a general population with improved cancerfree survival when compared with symptomatic patients 116 . Although most cases are sporadic 62 , the majority of patients with RCC might have a genetic predisposi tion 38, 117 . Although, no guideline is available regarding the selection of patients for germline mutation test ing, guidelines for monitoring those with confirmed hereditary syndromes that increase the risk of RCC are available 37 .
Prevention: modifiable risk factors
Smoking, obesity and hypertension are associated with increased risks of developing RCC, whereas exercise and moderate consumption of alcohol and flavonoids reduce the risks of RCC.
Smoking. When compared to never smokers, a relative risk for ever smokers of 1.38 (95% CI: 1.27-1.50) was reported in a metaanalysis including 8,032 cases and 13,800 controls from five cohort studies 118 . A dose dependent increase in risk in both men and women was found; individuals who had quit smoking >10 years prior had a lower risk than those who had quit <10 years prior. Another study has confirmed smoking as a risk factor for RCC 119 .
Obesity. A 5 kg/m
2 increase in BMI was found to be strongly associated with RCC 120 . Similarly, a strong associ ation between weight gain in early and mid adulthood (18-35 years of age) and RCC was reported 121 . Moreover, central adiposity (relative risk: 1.8; 95% CI: 1.2-2.5) and the waisttohip ratio (range: 0.86-2.88) were positively associated with RCC in women 122 . The effect of BMI on overall survival was also studied in 1,975 patients treated with targeted agents. The authors reported a median overall survival of 25.6 months (95% CI: 23.2-28.6) in patients with a high BMI versus 17.1 months (95% CI: 15.5-18.5) in patients with a low BMI (adjusted hazard ratio: 0.84; 95% CI: 0.73-0.95) 123 . Compared with stable weight, neither steady gain in weight nor weight loss was significantly associated with risk of RCC 121 .
Hypertension and medications. Higher BMI and hyper tension were independently shown to increase the long term risk of RCC in men, whereas a reduction in blood pressure lowered the risk 124 . Aspirin use was found to be associated with an increased RCC risk in one out of five studies 125 ; by contrast, paracetamol (also known as acetaminophen) exposure showed no increased risk 126 . The role of phenacetin (also known as acetophenetidin) exposure has been inconclusive 127 . Statins were reported to significantly reduce the risk of RCC in a large analy sis (n = 483,733), with a 48% risk reduction (adjusted odds ratio: 0.52; 95% CI: 0.45-0.60) 128 . However, owing to the sporadic and lowfrequency nature of RCC, the current guideline does not support the role of empiri cal treatment for the prevention of RCC in the general popu lation; patients with hereditary syndromes should be monitored more closely and treated accordingly.
Management
For patients with surgically resectable RCC, the stan dard of care is surgical excision by either partial or radical nephrectomy with a curative intent. By contrast, those with inoperable or metastatic RCC typically undergo systemic treatment with targeted agents and/or immune check point inhibitors. Deciding on which treatment to under take has been largely guided by various nomograms 30 . For example, the University of California, Los Angeles (UCLA) Integrated Staging System (UISS) and Stage, Size, Grade and Necrosis (SSIGN) score integrate clini cal (1997 TNM stage) and pathological (Fuhrman nuclear grade) information to recommend the length and fre quency of clinical followup and the selection of highrisk patients for adjuvant studies [129] [130] [131] . Similarly, key prognos tic factors have been identified, validated and adopted to guide and stratify patients with metastatic RCC for systemic treatment, including performance status, time from diagnosis to systemic treatment and haemoglobin, calcium and lactate dehydrogenase levels and neutrophil and platelet counts in the blood 99, 132, 133 .
Surgery
Surgical treatment of RCC is related to the clinical stage of the disease and to the general condition of the patient (FIG. 5) . Although typically reserved for localized disease, both partial and radical nephrectomy can also be used with cytoreductive intent in patients with metastatic disease. Indeed, randomized controlled trials (RCTs) demonstrating the benefit of this approach date from the 1990s, when cytokinebased therapies dominated the systemic therapy landscape. Furthermore, although most patients included in RCTs of targeted therapies also underwent cytoreductive nephrectomy, the current role of excision of the primary tumour in these patients has yet to be validated. However, according to the main international guidelines, many centres offer cytoreductive nephrectomy if there is a substantial disease volume at the primary site but only a low burden of metastatic disease 134 .
Partial nephrectomy. The goal of partial nephrectomy is to completely remove the primary tumour while pre serving the largest possible amount of healthy renal [135] [136] [137] and equivalent oncological survival outcomes compared with radical nephrectomy in those with T1 tumours 138, 139 . More con troversial is the favourable effect of partial nephrectomy on overall survival 140, 141 because conventional wisdom dictates that removal of the whole kidney is better in terms of oncological outcome. In this scenario, surgical feasibil ity remains the main factor that influences the final decisionmaking process.
In the past decade, nephrometry scoring systems have been proposed to predict the complexity of the partial nephrectomy procedure and to predict peri operative outcomes according to the anatomical and topographical tumour characteristics 142 (TABLE 3) . The R.E.N.A.L. and PADUA nephrometry systems are still the most popular and most used tools to preoperatively classify tumours 143 . These firstgeneration systems, along with the Centrality Index system, mainly factor in tumourrelated anatomical parameters, including face location (that is, anterior or posterior faces, according to their coverage by the anterior or posterior layers of the renal fascia, respectively), longitudinal polar loca tion, rim location (that is, whether the tumour is located at the lateral or medial rim of the kidney), the degree of tumour extension into the parenchyma, renal sinus involvement, upper urinary collecting system involve ment and the clinical maximal diameter of the tumour. Clinical studies demonstrated that such nephrometry systems were able to predict the risk of bleeding and postoperative complications in patients who underwent partial nephrectomy 142 . Thus, these systems represent valid tools for counselling patients and selecting the ideal candidate for partial nephrectomy according to surgeon experience 143 . Secondgeneration nephrometry systems, such as DiameterAxialPolar system, Zonal NePhRO scoring system and Arterial Based Complexity system, should be externally validated and tested headtohead against a firstgeneration system before being introduced into clinical practice. Available metaanalyses have demonstrated that RAPN provides equivalent perioperative outcomes to LPN but a significantly shorter warm ischaemia time 144, 145 . Moreover, RAPN seems to be significantly better than OPN in terms of perioperative complications, estimated blood loss and hospital stay 146, 147 . Conversely, trans fusion rate, ischaemia time, change in estimated glomerular filtration rate and early cancer outcomes are similar between the two approaches 147 . International guidelines recommend the use of both approaches according to the surgeon and patient preferences.
Finally, partial nephrectomy can also involve simple enucleation -entirely sparing the healthy parenchyma around the tumour. Alternatively, classic enucleo resection, in which a thin layer of healthy parenchyma is removed, or polar or wedge resection, in which a wider excision of healthy parenchyma is performed, are also viable options. A minimal tumourfree surgical margin following partial nephrectomy seems appropriate to avoid the increased risk of local recurrence 24 . Positive surgical margins have been reported in 1-6% of cases, regardless of the type of surgical technique used 148 . Haematuria, perirenal haematoma and urinary fistulas are the most common complications of partial nephrec tomy procedures. Lessfrequent postoperative compli cations can be represented by acute renal impairment and infection 149 .
Radical nephrectomy. Classic radical nephrectomy con sists of the removal of the kidney, perirenal fat tissue, adrenal gland and regional lymph nodes. However, in patients with a tumour ≤5 cm in size, located at the inferior pole, the adrenal gland can be spared. Similarly, regional lymph node dissection can be reserved for patients with clinically positive nodes detected by CT or during the surgical procedure 150 . Radical nephrectomy can be considered in cases with multiple small renal tumours, in cases in which the tumour extends into the vasculature and can be a laparoscopic or open proce dure (FIG. 6) . In most patients with stage I and stage II tumours, radical nephrectomy is currently performed using a traditional laparoscopic approach; the open approach remains the gold standard for the treatment of morecomplex cases. In experienced hands, the robot assisted approach can represent a potential alternative to open surgery in cases with venous tumour thrombus.
Data recently extracted from the US National Cancer Database support the use of cytoreductive nephrectomy in those with metastatic disease even while they receive systemic targeted therapies. Indeed, the median over all survival was 17.1 months in cytoreductive nephrec tomy cases versus 7.7 months in the noncytoreductive nephrectomy group 151 .
Active surveillance and ablative therapies
Active surveillance and ablative techniques, such as cryotherapy or radiofrequency ablation, are alternative strategies for elderly patients and/or those with compet ing health risks and limited life expectancy that render them unsuitable for surgery 15, 24 . A definite protocol for active surveillance has yet to be defined. The most common approach consists of alternating between ultrasonography imaging and CT or MRI every 3 months in the first year, every 6 months in the second year and annually thereafter. Intervention should be considered for growth to >3-4 cm or by >0.4-0.5 cm per year 152 . Data from the Delayed Inter vention and Surveillance for Small Renal Masses (DISSRM) registry in the United States showed that, in a wellselected cohort of patients with up to 5 years of pro spective followup, active surveillance was not inferior to primary intervention in terms of both overall survival and cancerspecific survival 26 . Ablative technology must be able to completely destroy all viable tumour tissue with no area of viable tumour left. Both cryotherapy and radiofrequency abla tion can be performed using a laparoscopic or percu taneous approach under CT or ultrasound guidance. A metaanalysis of case series showed 89% and 90% of efficacy for cryoablation and radiofrequency abla tion, respectively 25 ; complication rates were 20% and 19%, respectively. Available lowquality studies suggest a higher local recurrence rate for ablative therapies than for partial nephrectomy 153 .
Box 1 | Limitations in the management of non-clear-cell renal cell carcinoma
From the perspective of surgical management, the presence of non-clear-cell histology rarely has a bearing on treatment and, in fact, histological subtype is often unknown preoperatively. Limited data are available to guide medical management of non-clear-cell renal cell carcinoma (nccRCC) as a consequence of the exclusion in general of non-clear-cell histologies from registration trials of targeted agents over the past 10 years. Importantly, the tumours classed as nccRCC are fundamentally different; there is no reason to suppose that a therapy that is effective for papillary RCC would be effective for chromophobe or indeed any other subtype of kidney cancer. Nevertheless, some trials have been carried out and have broadly established sunitinib as a reasonable first-line option in nccRCC, although the efficacy is less than for clear cell renal carcinoma (ccRCC). Most patients with metastatic nccRCC are treated with targeted agents that are approved for ccRCC, with the data favouring vascular endothelial growth factor inhibitors over mechanistic target of rapamycin complex 1 inhibitors 22, 204, 205 . Unfortunately, most patients with nccRCC succumb to their disease within 18 months despite systemic treatment 12, 13, [204] [205] [206] , and currently, there is no evidence base for the treatment of nccRCC with immune checkpoint inhibitors. Encouragingly, a recent phase II trial reported everolimus plus bevacizumab as an effective combination in treating nccRCC in patients whose tumours display papillary features, achieving an overall response rate of 43% and a median progression-free survival of 12.9 months 194 . Arguably, everolimus plus bevacizumab should be considered as the comparison arm in trials in rare RCC subtypes that show predominant papillary morphology (papillary RCC type I and type II and unclassified RCC with papillary features). Overall, the advances made are encouraging, but drug therapies that are tailored specifically to subtype remain an unmet need. Initiatives such as rarekidneycancer.org set up by experts and patient advocates are important steps to encourage rapid communication among patients with rare kidney cancer, doctors who specialize in nccRCC and trialists.
Medical management
The past 10 years have seen the approval of several tar geted therapeutic agents and one immunotherapy agent for the treatment of metastatic RCC (FIG. 7) . However, in the adjuvant setting after surgery, the situation is less clear and a randomized trial (ASSURE) of sunitinib versus sorafenib versus placebo showed no benefit for either drug therapy in terms of diseasefree survival 131 .
Notably, a recent study in the adjuvant setting reported a diseasefree survival benefit for 1 year of sunitinib therapy in comparison with observation in the STRAC trial 130 . Several other trials of adjuvant targeted thera pies (such as PROTECT and SORCE) have completed accrual and will report outcomes in the next 12 months.
Targeted therapies. Given the highly vascular nature of RCCs, it is unsurprising that several therapies are available to exploit this feature. Indeed, tyrosine kinase inhibitors targeting the VEGF signalling axis that are approved in the firstline and secondline settings for the treatment of metastatic RCC in the United States and the European Union are sorafenib, sunitinib, pazopanib, axitinib, lenvatinib and cabozantinib [154] [155] [156] [157] [158] [159] . All approvals have been as single agents, except the combination of lenvatinib with everolimus; in addition, the antiVEGF monoclonal antibody bevacizumab is approved for use with interferonα 160, 161 . Broadly speaking, sunitinib, pazopanib and the combination of bevacizumab and interferonα are approved as firstline options, whereas axitinib and cabozantinib are approved as secondline options. The mTOR inhibitors everolimus and temsiroli mus are approved as single agents in the secondline set ting and in the firstline setting in patients with poor risk status 162, 163 . Indeed, arguably the landmark trial of firstline systemic therapy of metastatic RCC was the phase III study of sunitinib versus interferonα reported in 2007, in which the superiority of sunitinib in terms of response rate, progressionfree survival and overall survival was reported 155 . This trial established sunitinib as the standard of care and the drug remains the com parator for all currently recruiting phase III studies of new drugs.
No clinically usable markers are available to select patients for particular therapies, despite intensive efforts. As such, the average duration of disease control with these drugs is 8-9 months in the firstline setting and 5-6 months in the secondline setting. Most of the phase III RCTs leading to the approval of these agents have excluded patients with nccRCC (BOX 1) and, as such, this evidence base relates largely to ccRCC. Furthermore, all of these agents are given continuously until disease progression in the absence of major toxicity. In addition, alternative schedules, such as those electively inter rupting therapy for prolonged periods, have not been reported from RCTs.
Immunotherapy. Cytokines such as interferonα and highdose IL2 that enhance antitumour immune activ ity have been used since the 1990s to treat metastatic RCC and were standards of care before the introduction of sunitinib 164 . Both drugs typically benefit only a small subset of patients (generally those with intrin sically favourable disease biology) and are associated with substantial toxicity, particularly in the case of highdose IL2. Many studies are currently investigating combin ations of antiVEGF therapy with a new generation of immunotherapy agents in the form of T cell immune checkpoint inhibitors, such as antibodies against pro grammed cell death protein 1 ligand 1 (PDL1), which include avelumab and atezolizumab, and antibodies against programmed cell death protein 1 (PD1), which include nivolumab and pembrolizumab. PD1 negatively regulates T cell function and its ligand PDL1 is highly expressed by cancer cells; accordingly, blockade of the PD1-PDL1 axis promotes T cell activation and immune killing of the cancer. Another combination under investi gation (CheckMate 214; NCT02231749) is nivolumab with ipilimumab, an inhibitor of the T cell checkpoint cytotoxic T lymphocyteassociated protein 4 (CTLA4). CTLA4 also downregulates T cell function; its inhibition by these antibodies promotes T cell activation.
Nivolumab was approved in the United States and the European Union after the CheckMate 025 RCT showed an overall survival benefit compared with everolimus in patients who had failed prior therapy with sunitinib and pazopanib 165 . However, the response rate to nivolumab was only 25% (5% for everolimus) and most patients treated did not experience significant tumour shrink age. Although these checkpoint inhibitors show prom ise, predicting response is difficult. For example, in the CheckMate 025 trial, PDL1 expression did not correlate with response, as had been reported in other trials in other cancer types 165 . The reason for this observation is unknown, but PDL1 expression is dynamic in space and time, and archival (paraffinembedded) material from the primary tumour used in the CheckMate 025 trial might not have been representative of PDL1 expression at metastatic tumour sites. Finally, nivolumab is well tolerated compared with everolimus. Furthermore, it has been possible to com bine nivolumab (and other antiPD1 or antiPDL1 thera pies) with 'clean' (that is, morespecific, lesstoxic and easier to combine) antiVEGF therapies, such as axitinib and bevacizumab, leading to several phase III studies of such combinations in metastatic RCC.
Quality of life
Quality of life and patientreported outcomes have become an important way to assess therapeutic strat egies in the treatment of patients with RCC. Adverse events are important to consider and these are summar ized in TABLE 4. Although oncological outcomes such as survival are more objective, validated measures of quality of life have been developed to help assess the patient experience.
For localized RCC, a systematic review was per formed, which included data from 29 studies that inclu ded randomized and nonrandomized studies 149 . This review noted that qualityoflife outcomes after partial nephrectomy were superior to those of radical nephrec tomy regardless of approach or technique. Interestingly, no good evidence suggested that cryo therapy or radio frequency ablation had better qualityoflife outcomes than nephrectomy.
For metastatic RCC, measures of quality of life become more important as treatment is usually palliative and patients continually balance quality versus quantity of life. A validated 15question tool called the Func tional Assessment of Cancer TherapyKidney Cancer Symptom Index (FKSI) is the most specific to kidney cancer 166 . A subscale of this, the FKSIDRS (diseaserelated symptoms) has nine kidney cancerspecific questions on the topics of lack of energy, pain, weight loss, bone pain, fatigue, shortness of breath, cough, fever and haema turia. Other moregeneral questionnaires exist and have been used in RCC clinical trials, including the Functional Assessment of Cancer Therapy General (FACTG), the EuroQOL EQ5D and Visual Analogue Scale (VAS) 167 . These tools enable investigators to assess quality of life; however, limitations, including question naire burden, incomplete answering and defining a truly clinically significant minimal difference in qualityoflife scores, remain.
In the phase III registration trial of firstline sunitinib versus interferonα in the metastatic setting, the FKSI, FKSIDRS, FACTG, EQ5D and EQVAS demonstrated a consistent favourable difference in quality of life for sunitinib 155 . This finding can probably be attributed to the favourable adverseeffect profile of sunitinib, which is associated with less fatigue than interferonα, and higher efficacy of sunitinib (31% response rate) than interferonα (6% response rate).
Quality of life was assessed with FKSI19, the Func tional Assessment of Chronic Illness Therapy Fatigue (FACITF), the Cancer Therapy Satisfaction Questionnaire (CTSQ) and the Seville Quality of Life Questionnaire (SQLQ) in the COMPARZ clinical trial, which compared firstline sunitinib versus pazo panib 156 . Measurements were taken at baseline and at day 28 of each treatment cycle, which is typically the point of highest sunitinib toxicity (including soreness in the mouth, throat, hands and feet). Improved quality oflife scores were observed in those patients taking pazopanib versus those taking sunitinib. The immune checkpoint inhibitors have also had qualityoflife analyses reported 167 . The CheckMate 025 study of nivolumab used the FKSIDRS score, which was performed at baseline and every 4 weeks up to study week 104, after which assessments were reduced. Median time to improvement in healthrelated quality of life was shorter in patients given nivolumab (4.7 months; 95% CI: 3.7-7.5) than in patients given everolimus (median not reached). The overall survival of patients was longer in those who had high baseline healthrelated qualityoflife scores who then improved than in those with similar baseline scores whose scores then deterior ated. The shortest overall survival was observed in patients with low baseline scores who then deteriorated.
Outlook
With the considerable advances in the molecular biology and management of RCC over the past several decades, it is not without reason that one could describe the cur rent era of knowledge and available treatments as the 'golden age' of research. If we are to progress further, advances in diagnosis, local management and systemic therapy are needed to achieve >80% longterm survival that might define the future 'diamond age' of kidney cancer research and therapy (FIG. 7) . Areas that currently show promise include developing strategies for treating highrisk patients, biomarkers to guide treatment and preventing and overcoming drug resistance.
Biomarkers to guide treatment
Although wide ranging clinical outcomes can be attrib uted to tumour heterogeneity in RCC, opportunities to further improve clinical outcomes on the basis of individual tumour characteristics (socalled precision medicine) are an emerging field. Given that nivolumab, cabozantinib and lenvatinib were only recently approved, and few correlative studies have been reported, potential biomarkers for VEGF and mTOR inhibitors currently have the most promise.
Biomarkers can range from clinical parameters (such as blood pressure) and endogenous substances (such as plasma proteins) to pathobiological features that are specific to individual tumours (such as muta tions). For example, as an ontarget clinical biomarker, hypertension (a systolic blood pressure of ≥140 mmHg) in patients receiving VEGF inhibitors has been shown to be associated with improved progressionfree survival and overall survival 168 . In addition, many studies have looked into circulating biomarkers 169 , among which high levels of IL6, IL8, hepatocyte growth factor and osteopontin were associated with shorter progression free survival in patients receiving pazopanib and sunitinib 170, 171 , whereas high levels of lactate dehydrogen ase were associated with better overall survival in those receiving temsirolimus but not interferonα 172 . Genetic biomarkers are also beginning to be stud ied for associations with treatment outcome in various meta static settings [173] [174] [175] . For example, RECORD3, a large randomized phase II trial (n = 471), demonstrated the better firstline efficacy of sunitinib (a progression free survival of 10.7 months) over firstline everolimus (a progressionfree survival of 7.9 months) 22 . Inter estingly, genomic biomarker analysis of patients enrolled in RECORD3 showed that BAP1 mutations were associ ated with a progressionfree survival of 8.1 months with firstline sunitinib but 5.5 months with firstline everolimus -a significant difference. By contrast, PBRM1 mutations showed no such associ ation 20 , which is consistent with a VEGF inhibitor out lier study 173 and warrants further validation. That BAP1 mutations were associated with inferior outcomes on everolimus 20 is surprising given their reported higher mTORC1 activity than PBMR1mutant tumours 70 . Furthermore, patients with KDM5C mutations were associated with a much longer firstline progressionfree survival with sunitinib (20.6 months) than with everoli mus (9.8 months) 20 . As mutual exclusivity was detected between mutations in BAP1 and PBRM1 or KDM5C 20 , molecular subgrouping of metastatic ccRCC based on these three genes could be of clinical value in the future. In addition, casebased mTOR inhibitor outlier studies recognized activation mutations of MTOR and biallelic inactivation of TSC1 or TSC2 as potential biomarkers for longterm responders 69, 73, 75, 76 .
Managing high-risk patients
A significant number (~30%) of patients with non metastatic disease (based on clinical and pathological evaluation at the initial diagnosis) have occult metasta ses that will eventually become clinically evident. How to identify and better manage these highrisk patients presents a major challenge for operating urologists. As we begin to appreciate the effect that prevalent RCC mutations (in PBRM1, SETD2, BAP1, KDM5C, PTEN and TP53) have on clinical outcomes, incorporating specific mutational information into prognostic nomo grams will become increasingly useful. For example, transcription signatures, such as ClearCode34 (REF. 86 ), and other biomarkers in the blood and urine might be incorporated into validated predictive biomarkers for RCC recurrence after surgery. Similarly, predict ing treatment response to systemic therapy might be plausible and will reduce cost and improve care for patients with RCC. Our improving ability to identify highrisk patients with RCC and formulate personalized treatment and followup plans based on multiomics holds the promise to quickly reduce the incidence of patients developing overt metastatic disease and render longterm survival.
Emerging therapies and changes to treatment
Several promising new drugs with novel mechanisms of action are in various stages of clinical trials. For immuno therapeutics, ipilimumab, an antiCTLA4 antibody, in combination with nivolumab has shown a remarkable response rate of ~40% in the CheckMate 016 trial 176 . In addition, the efficacy of autologous dendritic cellbased immunotherapy, which consists of expanding the patient's own dendritic cell numbers in vitro followed by the introduction of tumour RNA before reinfusion back into the patient, in combination with sunitinib has been examined and has shown early promise 177 .
In the realm of targeted therapeutics, inhibitors specifi cally targeting HIF2 have been developed 178, 179 . As kidney cancer is characterized by aberrant glycolysis (with aber rant glutamine and tryptophan metabolism 65, 180, 181 ), it is of interest to learn whether the glutaminase inhibitor CB839 (REF. 182 ) and the indoleamine2,3dioxygenase inhibitor INCB024360 (REF. 183 ) could yield additional clinical bene fits when added to existing therapies. Finally, as many of these novel therapeutic agents act on modulating the anticancer response in patients, further understanding of the intricate relationship between an individual kidney cancer cell and its respective immune microenviron ment would be crucial for the future success in designing combination treatments to improve survival 87, [184] [185] [186] [187] . Given the increasing understanding of tumour bio logy and the increasing number of treatment options, how treatments are selected in the future will undoubt edly change (FIG. 8) . In addition to those already dis cussed, potential treatments of high value might include personalized vaccination 188 , targeted radiotherapy to enhance antitumour immune response 189 and selec tive cytoreductive nephrectomy in patients who were initially inoperable but later showed marked shrinkage of tumours after systemic treatments. Furthermore, neoadjuvant or adjuvant 190 immunotherapy or tar geted therapy could become integrated into the current treatment algorithms.
Preventing and overcoming drug resistance
Model systems and clinical experience have shown that inhibiting RCC activity with multiple drugs speci fic to different targets is superior to singleagent approaches 23, 191, 192 . However, such approaches tend to produce more toxicities -ontarget and offtarget. For example, the combination of sunitinib and everolimus in treating metastatic RCC subjected patients to severe toxicity 193 . Nevertheless, bevacizumab, a more tolerable VEGF pathway inhibitor than sunitinib, plus everoli mus is well tolerated and has been shown to be effica cious in treating nccRCC with papillary features 194 . The success of polypharmacy relies on efficient and correct targeting of both primary and secondary (bypass) path ways 69, 195 . In ccRCC, VEGF is the primary pathway due to the universal VHL loss; secondary targets can include mTORC1, MET and IL8, but not epidermal growth factor receptor or phosphoinositide 3kinase path ways, when one takes into consideration the available clinical 158, 159, 169, 196, 197 and preclinical studies 92, [198] [199] [200] . Given the availability of targeted therapies (FIG. 7) , the immediate challenge is to design the most effective and specific regimen through combining or sequenc ing drugs to prevent resistance in individual patients 201 .
Interestingly, a recent study in patients with melanoma who relapsed after initial treatment response on PD1 blockade revealed invaluable insights on how tumour cells might develop resistance to immunotherapies, including defects in interferon signalling and in anti gen presentation 202 . As immune checkpoint inhibitors function independently of specific oncogenic path ways and incur distinct resistance mechanisms 202 , the combin ation of these drugs with targeted therapies is of great clinical interest 203 and theoretically can prevent the emergence of escape mechanisms from either agent.
